Randomized trials have shown that selective serotonin reuptake inhibitors (SSRIs) and
serotonin-norepinephrine reuptake inhibitors (SNRIs) have better safety profiles than …

Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major
depressive disorder (MDD) in adults. It is formulated into tablets and has a dose range of 5 …

This chapter covers antidepressants that fall into the class of serotonin (5-HT) and
norepinephrine (NE) reuptake inhibitors. That is, they bind to the 5-HT and NE transporters …

Patients with mental disorders have an increased risk to develop cardiovascular disease
(CVD), and CVD are frequently comorbid with especially adjustment, anxiety and depressive …

Depression is a common psychological disease with high morbidity and mortality. Recently,
the involvement of synaptic plasticity in the pathogenesis of depression has shed light on the …

Résumé Contexte Le Réseau canadien pour les traitements de l'humeur et de l'anxiété
(CANMAT) a publié les dernières lignes directrices cliniques pour le traitement du trouble …

Vortioxetine hydrobromide is a common clinical medication for major depressive disorder
(MDD). However, it remains unclear whether vortioxetine hydrobromide acts by affecting the …

Repurposing ketamine in the therapy of depression could well represent a breakthrough in
understanding the etiology of depression. Ketamine was originally used as an anesthetic …

Vilazodone is a novel antidepressant used for the treatment of major depressive disorder
(MDD) with a primary action mechanism of inhibiting the human serotonin reuptake …

Introduction Major depressive disorder (MDD) is a highly prevalent and burdensome
condition. This study aims to evaluate the effectiveness, tolerability, and safety of vortioxetine …